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4.3 years (3 month–6 years). One patient died three months after the end of the treatment due to the tumor spread in CSF. We
observe local control at 1-year follow-up in 13 of the remaining patients (81%). Two patients relapsed in the cavernous sinus and
in Eustachian tube/middle ear respectively. Both patients were subsequently treated with reirradiation using IMRT achieving
a complete response that persists nowadays. Two patients (12%) died from lung metastasis without evidence of local relapse.
Side-effects: nasal dryness 60%, G1 and G2 xerostomia (33% and 7% of patients respectively), otitis media in 40%, esophageal
stenosis 7%. One of three patients with pericarotid tumor involvement developed massive hemorrhage due to the rupture of a
carotid aneurysm that required urgent vascular surgery. IMRT was associated with excellent local control and survival. Inclusion
of more patients and a longer follow-up are required to conﬁrm these results
http://dx.doi.org/10.1016/j.rpor.2013.03.268
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Background. We conducted a prospective study in patients with locoregionally advanced head and neck squamous cell can-
cer (LAHNC) to evaluate the feasibility and efﬁcacy of combining 3-drug taxane-containing induction chemotherapy (IC) with
radiation and concomitant single-agent cetuximab or cisplatin.
Methods. Three cycles of TPF induction chemotherapy with prophylactic G-CSF followed by deﬁnitive radiation and concurrent
cetuximab (400mg/m2 loading dose and 250mg/m2 per week during RT) or cisplatin (30mg/m2/w or 100mg/m2 120-h continuous
infusión of weeks 1 and 5). Radiotherapy was delivered with accelerated hyperfractionation concomitant boost (72Gy/42 fr/6w)
or standard fractionation (70Gy/35 fr/7w).
Results. There were 51 eligible and evaluable patients enrolled between May 1, 2007, and August 31, 2012. According to the AJCC 6
ed., 2010, 48 (94%) had stage IV disease and 3 (5.9%) stage III. Larynx 24 (45.5%) was the most common site followed by oropharynx
10 (19.6%), hypopharynx 10 (19.6%), oral cavity 3 (5.9%), nasopharynx 2 (3.9%) and paranasal sinus 1 (1.9%). Concurrent with
radiotherapy 42 patients (82.3%) received cetuximab and 9 patients (17.6%) cisplatin. The percentage of patients completing ICT
was 98.04%, radiation 100%, and cetuximab or cisplatin 98%. During TPF G 3 non-haematological toxicity occurred in 7 patients
(13.7%) and G4 in 2 (3.9%). Acute G 3–4 toxicity of concurrent treatment included dermatitis in 37 patients (36 G3, 1 G4) and
mucositis in 39 (38 G3, 1 G4). Forty-ﬁve percent of patients received enteral feeding. The overall response rate was 94.1%. Tumor
response (RECIST) at 12 weeks following completion treatment was 64.7% complete response and 29.4% partial response. The
2.5-year overall survival estimates were 58.1%, with 2.5-year progression-free survival estimates of 55.3% and 2-year local control
estimates of 81.3%.
Conclusions. Triple drug-based sequential therapy in patients with LAHNC is tolerable, with encouraging efﬁcacy.
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Purpose. Is described our experience in protocol for adaptive radiotherapy for head and neck tumors treated with Boost integrated
IMRT.
Material and method. IMRT in head and neck cancer provides an essential role in such diseases, and this technique provides a high
level of coverage with a low threshold dose distribution in critical organs (cord, brainstem, mandible, parotid glands), comparing
to 3D conventional technique. (a) Starting from 2011 we began conducting the protocol to assess replanning in IMRT: a new
CT-scan is performed at 4 weeks from starting treatment and is fussioned with the preplanning-CT as a dose of 45Gy; when
there nodal regression and inclusion of the parotids to the high dose region, and for that dose, weight loss is more apparent on
the anatomical structures of the head and neck. (b) 79 patients were treated between 2011 and 2012 with the diagnosis head
and neck cancer. We report our experience for replanning in IMRT treatment. (c) 14 of 79 patients (17%) were replaniﬁcated with
